MCS Medical Compression Systems (DBN) Ltd. (TASE:MDCL) has obtained US Food and Drug Administration (FDA) marketing approval for its ActiveCare + DT non-invasive device for treating deep vein thrombosis and preventing embolisms. The company will begin marketing the system in 2012.
MCS says that the system, a development of its flagship ActiveCare + SFT device, is the only device on the market that combines simultaneous diagnostics with treatment during preventative care by identifying disruptions in blood flow in the limb veins in real time and preventing its development. The company added that, currently, there is a 5-6% risk of developing deep vein thrombosis in patients who receive medication and/or other therapy after orthopedic surgery, but there no treatments or technologies to warn that the therapy is failing.
MCS says that the ActiveCare + DT system can more quickly identify the development of deep vein thrombosis early in post-operative care and verify the presence of blood clots. Early diagnosis should greatly reduce severe complications, such as potentially lethal pulmonary embolisms.
A large clinical trial in the US found that use of ActiveCare + SFT with the blood thinner Lovenox on patients after knee replacement surgery was effective MCS says that the ActiveCare + DT system has an advantage over medication by providing early diagnosis in patients where preventative care has failed.
MCS's share price rose 2% by midday to NIS 4.02, giving a market cap of NIS 163 million.
No comments:
Post a Comment